Ipragliflozin

Iupac Name：(2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

CAS No.: 761423-87-4

Molecular Weight：404.5

Introduction: Ipragliflozin L-proline was approved in Japan in January 2014for the treatment of type 2 diabetes. The drug was discovered byAstellas Pharma and co-developed and marketed with KotobukiPharmaceutical and Merck Sharp Dohme as Suglat?. Similar toempagliflozin (XIII), ipragliflozin L-proline is a sodium-glucose1956 A. C. Flick et al. / Bioorg. Med. Chem. 24 (2016) 1937–1980co-transporter-2 inhibitor which prevents glucose reabsorption byexcreting excess glucose in the urine. Ipragliflozin exhibitsremarkable selectivity over SLGT-1 (>250x).